All Photos(1)

Documents

Y0001288

Salbutamol sulfate for system suitability

Name: Salbutamol sulfate for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Salbutamol hemisulfate salt, α₁-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt, Albuterol sulfate

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₃H₂₁NO₃ · 0.5H₂SO₄

CAS Number:

51022-70-9

Molecular Weight:

288.35

MDL number:

MFCD00055200

UNSPSC Code:

41116107

PubChem Substance ID:

329831344

NACRES:

NA.24

Recommended Products

Slide 1 of 7

1 of 7

S0150000

Salbutamol sulfate

BP302

Salbutamol sulfate

Y0000465

Ticarcillin monosodium

Supelco

PHR1053

Albuterol sulfate

Y0001186

Salbutamol impurity J

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate

C0100000

Caffeine

grade

pharmaceutical primary standard

API family

albuterol, salbutamol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

InChI key

BNPSSFBOAGDEEL-UHFFFAOYSA-N

Gene Information

human ... ADRB2(154)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Materials for the Pharma Industry

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Salbutamol sulfate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1012644

1012655

1012689

BP302

Salbutamol sulfate, British Pharmacopoeia (BP) Reference Standard

PHR1960

Salbutamol Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1962

Salbutamol impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

BP712

Salbutamol aldehyde impurity, British Pharmacopoeia (BP) Reference Standard

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate, British Pharmacopoeia (BP) Reference Standard

BP852

Salbutamol impurity B, British Pharmacopoeia (BP) Reference Standard

BP704

Salbutamol ketone impurity, British Pharmacopoeia (BP) Reference Standard

PHR2106

4-[2-[(1,1-Dimethylethyl)amino]ethyl]-2-methylphenol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9050

4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol, reference material, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

1012564

PHR2332

Methyl5-[2-[benzyl(tert-butyl)amino]acetyl]-2-hydroxybenzoate hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

GHS07,GHS08

Signal Word

Warning

Hazard Statements

H317 - H351 - H361fd

Precautionary Statements

P202 - P261 - P272 - P280 - P302 + P352 - P308 + P313

Hazard Classifications

Carc. 2 - Repr. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Sigma-Aldrich

S5013

Salbutamol hemisulfate salt

Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Helgo Magnussen et al.

The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)

Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.

Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial.

Todd A Florin et al.

JAMA pediatrics, 168(7), 664-670 (2014-05-28)

Acute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there are no effective therapies available. Current evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronchiolitis. To determine whether nebulized

Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial.

Susan Wu et al.

JAMA pediatrics, 168(7), 657-663 (2014-05-28)

Bronchiolitis is one of the most common and costly respiratory diseases in infants and young children. Previous studies have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency department (ED) setting is unclear. To compare

Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.

Dwight D Koeberl et al.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(5), 2171-2176 (2014-01-21)

Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased

Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.

B Padhukasahasram et al.

The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)

Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service